COVID-19 Prevalence in HIV-infected Patients (SeCoVIHA)

University Hospital, Strasbourg, France

Status: Unknown

Conditions: HIV Infections

Treatments: Other: Blood Sample

Study type: Observational

Funder types: Other

Identifiers

NCT04515225

7947

Details and patient eligibility

About

North-east area of France was hit in February 2020 by the new coronavirus disease, more severely than other French regions. Factors affecting the evolution of the disease and its severity have been quickly identified, among them figuring different kinds of immune deficiency. Even if nowadays HIV infection is usually well controlled by ARV drugs, those patients with uncontrolled viral load and/or low CD4 cell counts, remain at higher risk of severe COVID infection. In this context, the primary objective of our study is aimed at evaluating the prevalence of SARS-CoV-2 antibodies in a cohort of HIV-infected patients followed-up in an HIV-infection care center. Secondary objectives are: evaluating whether the antibodies are protective or not, the kinetic of these antibodies, and HIV associated factors with the presence of antibodies.

Enrollment: 500 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• adults (> 18 years)
• HIV-infected patients
• subjects with social insurance
• subjects able to understand study purposes, and to give a written and informed consent

Exclusion Criteria :

• subjects unable to understand informations on the study, and to provide informed consent
• subjects under guardianship or curatorship
• subjects under judicial protection

Trial design

500 participants in 1 patient group

HIV-infected patients

Description:

All HIV-infected patients on active follow-up, whatever clinical and biological condition, on ARV treatment or not, and whatever ARV combination

Treatment:

Other: Blood Sample